Transcriptomics analysis of sirolimus treatment in lupus nephritis

Wang,Dongdong; Chen,Xiao; Fu,Meng; Li,Zhiping

doi:10.3892/mmr.2019.10238

Transcriptomics analysis of sirolimus treatment in lupus nephritis

Authors:
- Dongdong Wang
- Xiao Chen
- Meng Fu
- Zhiping Li
View Affiliations

Affiliations: Department of Pharmacy, Children's Hospital of Fudan University, Shanghai 201102, P.R. China, Department of Pharmacy, The People's Hospital of Jiangyin, Jiangyin, Jiangsu 214400, P.R. China
Published online on: May 14, 2019 https://doi.org/10.3892/mmr.2019.10238
Pages: 245-251
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lupus nephritis (LN) is one of the principal causes of mortality and disability in patients with systemic lupus erythematosus. Sirolimus has been used to treat patients with LN; however, the effects and mechanism of sirolimus in these patients remains unclear. The present study aimed to elucidate the therapeutic effects and mechanisms of sirolimus in LN mice using low, medium and high doses of sirolimus (0.1, 0.3 and 1 mg/kg, respectively). The survival probability and kidney index were calculated, and renal fibrosis was determined using Masson's Trichrome staining. The expression levels of E‑cadherin, α‑smooth muscle actin (α‑SMA) and vimentin were assessed via immunofluorescence analysis. Transcriptome analysis of control and sirolimus‑treated LN mice was performed using RNA‑sequencing, differentially expressed gene (DEG) identification and annotation, and Gene Ontology (GO) functional and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. The results suggested that a medium dose of sirolimus alleviated renal fibrosis and increased the survival rates of mice with LN (P<0.05). Furthermore, transcriptome analysis revealed 334 DEGs associated with LN, 176 of which were upregulated and 158 were downregulated. Following GO functional enrichment, ‘biological process’, ‘molecular function’ and ‘cellular component’ terms were identified. A total of 10 KEGG pathways were enriched, with ‘cytokine‑cytokine receptor interaction’ and ‘interleukin‑17 signaling pathway’ being significantly enriched (P<0.05). To the best of our knowledge, the present study is the first to conduct transcriptome analysis of LN mice treated with sirolimus, and demonstrated that a dose of 0.3 mg/kg exerted the greatest therapeutic effects.

View Figures

View References

1	Wang DD, Lu JM, Li Q and Li ZP: Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. J Clin Pharm Ther. 43:476–483. 2018. View Article : Google Scholar : PubMed/NCBI
2	Takeuchi T, Tsuzaka K, Abe T, Yoshimoto K, Shiraishi K, Kameda H and Amano K: T cell abnormalities in systemic lupus erythematosus. Autoimmunity. 38:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
3	Rahman A and Isenberg DA: Systemic lupus erythematosus. N Engl J Med. 358:929–939. 2008. View Article : Google Scholar : PubMed/NCBI
4	Gurevitz SL, Snyder JA, Wessel EK, Frey J and Williamson BA: Systemic lupus erythematosus: A review of the disease and treatment options. Consult Pharm. 28:110–121. 2013. View Article : Google Scholar : PubMed/NCBI
5	D'Cruz DP, Khamashta MA and Hughes GR: Systemic lupus erythematosus. Lancet. 369:587–596. 2007. View Article : Google Scholar : PubMed/NCBI
6	Liao R, Liu Q, Zheng Z, Fan J, Peng W, Kong Q, He H, Yang S, Chen W, Tang X and Yu X: Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis. PLoS One. 10:e01327242015. View Article : Google Scholar : PubMed/NCBI
7	Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, et al: EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the eular standing committee for international clinical studies including therapeutics. Ann Rheum Dis. 67:195–205. 2008. View Article : Google Scholar : PubMed/NCBI
8	Ji Y, Chen S, Xiang B, Li K, Xu Z, Yao W, Lu G, Liu X, Xia C, Wang Q, et al: Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study. Int J Cancer. 141:848–855. 2017. View Article : Google Scholar : PubMed/NCBI
9	Jung KS, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK and Kim ST: Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. Mol Clin Oncol. 7:27–31. 2017. View Article : Google Scholar : PubMed/NCBI
10	Djebli N, Rousseau A, Hoizey G, Rerolle JP, Toupance O, Le Meur Y and Marquet P: Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. Clin Pharmacokinet. 45:1135–1148. 2006. View Article : Google Scholar : PubMed/NCBI
11	Jiao Z, Shi XJ, Li ZD and Zhong MK: Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. Br J Clin Pharmacol. 68:47–60. 2009. View Article : Google Scholar : PubMed/NCBI
12	Wataya-Kaneda M, Nakamura A, Tanaka M, Hayashi M, Matsumoto S, Yamamoto K and Katayama I: Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: A randomized clinical trial. JAMA Dermatol. 153:39–48. 2017. View Article : Google Scholar : PubMed/NCBI
13	Wang DD, Lu JM, Li YZ, Li Q and Li ZP: Population pharmacokinetics of sirolimus in pediatric tuberous sclerosis complex: From real world study. Int J Clin Exp Med. 11:12302–12309. 2018.
14	Zhou L, Du GS, Pan LC, Zheng YG, Liu ZJ, Shi HD, Yang SZ, Shi XJ, Xuan M, Feng LK and Zhu ZD: Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience. Oncol Lett. 14:7817–7824. 2017.PubMed/NCBI
15	Zhou L, Pan LC, Zheng YG, Du GS, Fu XQ, Zhu ZD, Song JY, Liu ZJ, Su XZ, Chen W, et al: Novel strategy of sirolimus plus thymalfasin and huaier granule on tumor recurrence of hepatocellular carcinoma beyond the UCSF criteria following liver transplantation: A single center experience. Oncol Lett. 16:4407–4417. 2018.PubMed/NCBI
16	Fu J, Wang Z, Lee K, Wei C, Liu Z, Zhang M, Zhou M, Cai M, Zhang W, Chuang PY, et al: Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis. Kidney Int. 93:416–429. 2018. View Article : Google Scholar : PubMed/NCBI
17	Yap DYH, Tang C, Chan GCW, Kwan LPY, Ma MKM, Mok MMY and Chan TM: Longterm data on sirolimus treatment in patients with lupus nephritis. J Rheumatol. 45:1663–1670. 2018. View Article : Google Scholar : PubMed/NCBI
18	Liu J, Yang L, Hou Y, Soteyome T, Zeng B, Su J, Li L, Li B, Chen D, Li Y, et al: Transcriptomics study on staphylococcus aureus biofilm under low concentration of ampicillin. Front Microbiol. 9:24132018. View Article : Google Scholar : PubMed/NCBI
19	Kim D, Langmead B and Salzberg SL: HISAT: A fast spliced aligner with low memory requirements. Nat Methods. 12:357–360. 2015. View Article : Google Scholar : PubMed/NCBI
20	Wang K, Li M and Hakonarson H: ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI
21	Burden CJ, Qureshi SE and Wilson SR: Error estimates for the analysis of differential expression from RNA-seq count data. PeerJ. 2:e5762014. View Article : Google Scholar : PubMed/NCBI
22	Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar : PubMed/NCBI
23	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The gene ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
24	Seshan SV and Jennette JC: Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: Advances and implications. Arch Pathol Lab Med. 133:233–248. 2009.PubMed/NCBI
25	Tveita A, Rekvig OP and Zykova SN: Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis. Arthritis Res Ther. 10:2292008. View Article : Google Scholar : PubMed/NCBI
26	Kolset SO, Reinholt FP and Jenssen T: Diabetic nephropathy and extracellular matrix. J Histochem Cytochem. 60:976–986. 2012. View Article : Google Scholar : PubMed/NCBI
27	Wang D, Zhang G, Chen X, Wei T, Liu C, Chen C, Gong Y and Wei Q: Sitagliptin ameliorates diabetic nephropathy by blocking TGF-beta1/Smad signaling pathway. Int J Mol Med. 41:2784–2792. 2018.PubMed/NCBI
28	Chen X, Wang DD, Wei T, He SM, Zhang GY and Wei QL: Effects of astragalosides from radix astragali on high glucose-induced proliferation and extracellular matrix accumulation in glomerular mesangial cells. Exp Ther Med. 11:2561–2566. 2016. View Article : Google Scholar : PubMed/NCBI
29	Zhang GY, Wang DD, Cao Z, Wei T, Liu CX and Wei QL: Sitagliptin ameliorates high glucose-induced cell proliferation and expression of the extracellular matrix in glomerular mesangial cells. Exp Ther Med. 14:3862–3867. 2017. View Article : Google Scholar : PubMed/NCBI
30	Chen X, Yang Y, Liu C, Chen Z and Wang D: Astragaloside IV ameliorates high glucoseinduced renal tubular epithelialmesenchymal transition by blocking mTORC1/p70S6K signaling in HK2 cells. Int J Mol Med. 43:709–716. 2019.PubMed/NCBI
31	Badid C, Desmouliere A, Babici D, Hadj-Aissa A, McGregor B, Lefrancois N, Touraine JL and Laville M: Interstitial expression of alpha-SMA: An early marker of chronic renal allograft dysfunction. Nephrol Dial Transplant. 17:1993–1998. 2002. View Article : Google Scholar : PubMed/NCBI
32	Cao YH, Lv LL, Zhang X, Hu H, Ding LH, Yin D, Zhang YZ, Ni HF, Chen PS and Liu BC: Urinary vimentin mRNA as a potential novel biomarker of renal fibrosis. Am J Physiol Renal Physiol. 309:F514–F522. 2015. View Article : Google Scholar : PubMed/NCBI